Fannie Mae, Freddie Mac shares tumble after conservatorship comments
CHICAGO - Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a micro-cap company with a market value of $8.42 million specializing in AI-powered cardiovascular medicine, has been granted a patent by the Japan Patent Office, further expanding its international intellectual property portfolio. According to InvestingPro data, the company’s stock has shown significant volatility, with the price currently at $4.84, representing a notable recovery from its 52-week low. The patent, titled "Compositions and Methods for Detecting Predisposition to Cardiovascular Disease" (Japanese Patent No. 7672192), is exclusively licensed from the University of Iowa Research Foundation (UIRF).
The Japanese patent complements Cardio Diagnostics’ collection of patents in the United States, Europe, Australia, India, and China. These patents cover the company’s core technologies, which underpin its clinical solutions for cardiovascular disease prevention and detection. As a niche player in the healthcare technology sector, the company maintains a strong financial position with more cash than debt on its balance sheet, though InvestingPro analysis indicates rapid cash utilization in recent quarters.
CEO Meesha Dogan, Ph.D., emphasized the significance of the Japanese patent, viewing it as a key achievement in the company’s mission to globalize its precision cardiovascular medicine platform. The technology, which utilizes methylation and genetics-based diagnostics coupled with advanced machine learning algorithms, aims to enhance early detection and prevention of heart disease in markets worldwide, including Japan.
The UIRF, represented by Executive Director Marie Kerbeshian, Ph.D., expressed pride in supporting the innovation that emerged from the University of Iowa’s ecosystem. The UIRF anticipates that Cardio Diagnostics’ technology will have a meaningful impact on advancing cardiovascular medicine internationally.
This latest patent protects the company’s novel methods and compositions for assessing cardiovascular risk and detecting the disease using epigenetic and genetic biomarkers. Cardio Diagnostics is dedicated to providing data-driven solutions that offer healthcare providers and patients actionable insights for managing cardiovascular health, now extending its reach globally. While the company’s revenue growth forecast stands at 14.05% for the current year, InvestingPro subscribers can access 12 additional key insights about the company’s financial health and growth prospects, including detailed valuation metrics and analyst recommendations.
Cardio Diagnostics is known for its AI-driven Integrated Genetic-Epigenetic Engine, a core technology developed to enhance cardiovascular disease prevention, detection, and treatment. The company’s goal is to become a leading medical technology entity in the cardiovascular field. This press release statement provides information based on the company’s recent patent acquisition and ongoing efforts to broaden its global presence.
In other recent news, Cardio Diagnostics Holdings, Inc. has announced a 1-for-30 reverse stock split of its common stock, set to take effect on May 13, 2025. This move is intended to help the company comply with Nasdaq’s minimum bid price requirement for continued listing. The reverse stock split will consolidate every 30 existing shares into one share, reducing the outstanding common stock from approximately 52 million shares to about 1.7 million shares. Despite this consolidation, the authorized shares will remain at 300 million. The company’s ticker symbol will continue to be "CDIO," although a new CUSIP number will be assigned. The decision for the reverse stock split was authorized by stockholders and approved by the Board of Directors earlier this year. Additionally, the company’s 2022 Equity Incentive Plan and terms of outstanding warrants and stock options will be adjusted accordingly. This strategic move does not change Cardio Diagnostics’ focus on advancing its cardiovascular health technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.